Palvella Therapeutics Inc

Despite intact Stage 2 advancing structure and a secular uptrend, active Bullish Exhaustion and extreme overbought conditions suggest patience. The medium-term bias remains bullish, but execution should wait for a pullback into rising EMAs or support before engaging.

• ↑Phase III SELVA over-enrolled 51 vs 40 target, on track for 2H26 NDA
• ↑Q1 2026 cash of $261.9M post $230M financing funds operations into 2027
• ↓Negative earnings yield and weak profitability raise concerns on returns